TQB2922 not checked
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and…”In the company’s words, NCT07044908 on ClinicalTrials.gov
- Tested for
- RAS/BRAF Wild Type Colorectal Cancer, Colorectal Neoplasms, Recurrent/Metastatic Head and Neck Cancer, Advanced Cancer, Advanced Cancers
- Main trialPhase 1/2
- “This is a multicenter, open Phase Ib/II clinical study evaluating the safety and efficacy of TQB2922 in combination with TAS-102±bevacizumab in subjects with RAS/BRAF wild-type unresectable locally advanced or metastatic colorectal cancer that has failed treatment with oxaliplatin, fluorouracil-based and irinotecan.”In the company’s words, NCT07044908 on ClinicalTrials.gov
Other drugs for Colorectal Neoplasms
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up4
- DecPhase 1 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Feb 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jul 2026 | TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer | |
| Phase 1/2Not yet recruiting | 31 Aug 2027 | TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread | |
| Phase 1/2Not yet recruiting | Feb 2029 | Treatment of Recurrent/Metastatic Head and Neck Cancer | |
| Phase 1Recruiting | Dec 2026 | Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers | |
| Phase 1Recruiting | Dec 2029 | Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026